Large granular lymphocytic leukemia

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
3 regimens on this page
3 variants on this page


Guidelines

"How I Treat"

NCCN

Initial therapy

Cyclophosphamide monotherapy

back to top

Regimen

Study Evidence
Bareau et al. 2010 Retrospective

These are retrospective series, of which Bareau et al. 2010 is representative. The most common dose reported is 100 mg PO once per day; some authors mentions co-administration of steroids but details are not supplied.

Chemotherapy

Lamy et al. 2011 recommends that patients who are responding are continued on treatment for 6 to 12 months; patients who do not respond within 4 months of therapy are discontinued

References

  1. Retrospective: Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. link to original article PubMed
  2. Retrospective: Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. link to original article link to PMC article PubMed content property of HemOnc.org
  3. Retrospective: Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. link to original article link to PMC article PubMed

Methotrexate & Prednisone

back to top

Regimen

Study Evidence
Loughran et al. 2014 (ECOG E5998) Phase II

Chemotherapy

  • Methotrexate (MTX) 10 mg/m2/day PO in divided doses once per day on days 1, 8, 15, 22
    • Details not described in ECOG E5998; Lamy et al. 2011 divides the 10 mg/m2 methotrexate dose into 5 mg/m2 in the morning and 5 mg/m2 in the evening
  • Prednisone (Sterapred) 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)

28-day cycles

Subsequent treatment

  • Patients with PR: continue up to one year
  • Patients with CR: continue for one month past documented CR
  • Non-responders were transitioned to cyclophosphamide & prednisone

References

  1. ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains verified protocol link to PMC article PubMed

Relapsed or refractory

Cyclophosphamide & Prednisone

back to top

Regimen

Study Evidence Efficacy
Loughran et al. 2014 (ECOG E5998) Phase II ORR: 64% (95% CI, 35-87)

Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.

Preceding treatment

Chemotherapy

28-day cycles (see note)

References

  1. ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains verified protocol link to PMC article PubMed